AOD-9604 + CJC-1295: The Fat Loss Stack
AOD-9604
Modified GH fragment targeting direct fat metabolism without growth effects
CJC-1295
GHRH analogue stimulating pituitary GH release for indirect lipolysis
The AOD-9604 and CJC-1295 combination represents a dual-pathway approach to fat metabolism research. AOD-9604, a modified fragment of human growth hormone (amino acids 177-191), targets fat cells directly via β3-adrenergic pathways without producing GH-related growth effects. CJC-1295, a GHRH analogue, stimulates natural GH release from the pituitary, which indirectly promotes lipolysis through elevated GH and IGF-1.
By combining direct and indirect lipolytic mechanisms, this stack aims to enhance fat metabolism from two independent angles — potentially producing greater body composition effects than either peptide alone.
**Critical Disclaimer:** Neither AOD-9604 nor CJC-1295 is approved for human therapeutic use. AOD-9604 has GRAS status from the Australian TGA. This content is for educational and research purposes only.
Synergistic Mechanism
Dual-Pathway Fat Loss Synergy
AOD-9604: Direct Lipolysis
AOD-9604 acts directly on adipose tissue:
1. Stimulates lipolysis via β3-adrenergic receptor activation on fat cells
2. Inhibits lipogenesis (prevents new fat formation)
3. Does NOT elevate IGF-1 or produce GH-like growth effects
4. Does NOT affect glucose metabolism or insulin sensitivity
5. Selective fat metabolism without muscle, bone, or organ growth
CJC-1295: GH-Mediated Lipolysis
CJC-1295 promotes fat loss indirectly through GH elevation:
1. Binds GHRH receptors on pituitary somatotrophs
2. Stimulates natural GH synthesis and pulsatile release
3. Elevated GH activates hormone-sensitive lipase in adipose tissue
4. GH shifts fuel utilisation toward fat oxidation
5. IGF-1 elevation supports lean mass preservation during fat loss
The Synergy
These pathways are complementary:
- AOD-9604 acts directly on fat cells (local effect)
- CJC-1295 acts via systemic GH elevation (central effect)
- AOD-9604's lack of IGF-1 elevation means it doesn't overlap with CJC-1295's mechanism
- CJC-1295's lean mass preservation may offset any metabolic slowdown from fat loss
Research Evidence
Research Evidence
AOD-9604 Evidence
- Phase II trial (n=300): Modest but significant weight loss (2-2.8 kg vs 0.8 kg placebo over 24 weeks)
- GRAS status from TGA Australia confirms safety
- Preclinical data in obese Zucker rats showed selective fat reduction
- No IGF-1 elevation confirmed across studies
CJC-1295 Evidence
- Teichman et al. (2006): Single dose produced 2-10x GH elevation for 9-11 days (DAC version)
- GH-mediated lipolysis is well-established in endocrinology literature
- Elevated GH shifts substrate utilisation toward fat oxidation
- Body composition improvements associated with GH elevation in multiple contexts
Combined Evidence
No published studies have examined this specific combination. The rationale is based on complementary mechanisms from independent research.
We do not publish stack protocols
Peptide Authority does not publish doses, reconstitution recipes, injection schedules, or cycle lengths for combinations of unlicensed peptides. This is a deliberate editorial position — we are an evidence and risk-intelligence publisher, not a prescriber. The reasoning is set out in detail in our no dosing, no sourcing policy.
For an honest review of what proponents of this kind of combination claim versus what the published evidence actually supports, see the combination claim-reviews. If you are considering any peptide medicine, speak to a GMC-registered doctor or GPhC-registered pharmacist.
Expected Outcomes
Expected Research Outcomes
Based on individual peptide data (not combination):
- AOD-9604: Modest fat loss (2-3 kg over 12 weeks in clinical trials)
- CJC-1295: Body composition improvements associated with GH elevation
- Combined: Potentially enhanced fat loss through dual mechanisms
Realistic Expectations:
- This stack is not comparable to GLP-1 agonists (semaglutide produces 15%+ weight loss)
- No appetite suppression — caloric control must be maintained independently
- Exercise and diet remain the primary drivers of fat loss
- Peptides may provide a modest additional effect
Timeline:
- Weeks 1-2: No visible changes; GH and metabolic effects establishing
- Weeks 3-6: Subtle body composition changes may begin
- Weeks 6-12: Maximum effect period if combined with exercise and nutrition
Safety Considerations
Safety Considerations
AOD-9604 Safety:
- GRAS status provides basic safety assurance
- No IGF-1 elevation, no glucose effects, no GH-related side effects
- Injection site reactions possible
CJC-1295 Safety:
- Water retention (common, mild)
- Tingling/numbness
- Joint stiffness
- Potential insulin resistance with chronic use (monitor glucose)
- Flushing after injection
Combined Considerations:
- No known interactions between these peptides
- CJC-1295's GH effects are the main source of side effects
- AOD-9604 adds minimal additional risk
- Regular blood work recommended: glucose, insulin, IGF-1
- Discontinue if adverse effects occur
Frequently Asked Questions
Conclusion
The AOD-9604 + CJC-1295 stack offers a dual-mechanism approach to fat metabolism research. While neither peptide individually matches the efficacy of approved GLP-1 agonists, their complementary mechanisms — direct lipolysis and GH-mediated fat oxidation — provide an interesting research framework. Realistic expectations, proper monitoring, and maintained exercise/nutrition are essential.